Pharma Two B Presents Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at the MDS International Congress of Parkinson’s Disease and Movement Disorders®
P2B001 is a novel proprietary fixed-dose combination of extended-release (ER) formulations of low doses of pramipexole and rasagiline; both doses are not currently available on the market Phase 3 data support the potential of P2B001 as a first-line, once-daily treatment for people with Parkinson’s disease (PD), that may offer effective symptomatic control with significantly less … Read more